Case Report: Clinical and Procedural Implications of Ommaya Reservoir Implantation in Cystic Brain Metastases Followed by Radiosurgery Treatment

Lv, Junhui; Wu, Zhiyuan; Wang, Kun; Wang, Yirong; Yang, Shuxu; Han, Weidong

doi:10.3389/fsurg.2022.901674

Cited by 2 publications

(2 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Previous data suggest that the OS of cystic BMs is relatively better than that of solid BMs after systematic treatment, especially in patients undergoing EGFR TKI treatment [9]. Some evidence suggests that the development of cystic BMs may be related to the breakdown of the blood-brain barrier [14], allowing greater access to TKIs. Similarly, RT to the brain promotes neuroin ammation and disrupts the blood-brain barrier [15].…”

Section: Discussionmentioning

confidence: 99%

Evaluation of radiotherapy efficacy and prognostic analysis for solid and cystic brain metastases

sun,

Lin,

et al. 2024

Preprint

View full text Add to dashboard Cite

Purpose Brain metastases (BMs) are commonly categorized into cystic and solid. Despite advances in treatment modalities, the prognosis for patients with cystic and solid BMs following radiotherapy remains poorly understood. We use a retrospective design to elucidate the disparities in survival between these two patient groups undergoing radiotherapy and identify factors influencing overall survival (OS) of BMs in solid tumor. Methods This retrospective study encompasses 212 patients diagnosed with BMs. We meticulously analyzed the clinical characteristics, radiation therapy modalities, and risk factors influencing overall survival among these patients, categorized by BMs type, post-brain radiation therapy. Results A statistically significant difference in mOS was observed between the two cohorts (Solid vs. Cystic: 23.1 vs. 14.6 months). Subgroup analysis unveiled distinctions in mOS, particularly in patients with EGFR-mutant lung adenocarcinoma (Solid vs. Cystic: 23.1 vs. 6.43 months). The volume of BMs and the biological effective dose (BED) emerged as significantly prognostic factors for patients with cystic BMs. For patients with solid BMs, fraction dose, BED and the number of BMs were identified as independent prognostic factors for survival. Conclusion Brain radiotherapy shows superior survival benefits for lung cancer patients with solid BMs compared to those with cystic BMs, particularly in EGFR-mutant lung cancer. In particular, patients receiving BED ≥ 60Gy have a more favorable prognosis than those receiving BED < 60Gy, regardless of the type of BM (solid or cystic) in lung cancer.

show abstract

Section: Discussionmentioning

confidence: 99%

Evaluation of radiotherapy efficacy and prognostic analysis for solid and cystic brain metastases

sun,

Lin,

et al. 2024

Preprint

View full text Add to dashboard Cite

show abstract

“…Previous data suggest that the OS of cystic BMs is relatively better than that of solid BMs after systematic treatment, especially in patients undergoing EGFR TKI treatment. 9 Some evidence suggests that the development of cystic BMs may be related to the breakdown of the blood-brain barrier, 19 allowing greater access to TKIs. Similarly, RT to the brain promotes neuroinflammation and disrupts the blood-brain barrier.…”

Section: Discussionmentioning

confidence: 99%

Evaluation of Radiotherapy Efficacy and Prognostic Analysis for Solid and Cystic Brain Metastases

Sun,

Lin,

et al. 2024

Cancer Control

View full text Add to dashboard Cite

Objectives Brain metastases (BMs) are commonly categorized into cystic and solid. However, the difference in the prognosis of patients with either cystic or solid BMs following radiotherapy remains poorly understood. We used a retrospective design to elucidate the disparities in survival between these two patient groups undergoing radiotherapy and to identify factors influencing the overall survival (OS) of patients with BMs. Methods This retrospective study encompasses 212 patients diagnosed with BMs. We meticulously analyzed the clinical characteristics, radiation therapy modalities, and risk factors influencing the OS among these patients, categorized by BMs type, post-brain radiation therapy. Results A statistically significant difference in mOS was observed between the two cohorts (Solid vs Cystic: 23.1 vs 14.6 months). Subgroup analysis unveiled distinctions in mOS, particularly in patients with EGFR-mutant lung adenocarcinoma (Solid vs Cystic: 23.1 vs 6.43 months). The volume of BMs and the biological effective dose (BED) emerged as significantly prognostic factors for patients with cystic BMs. For patients with solid BMs, fraction dose, BED, and the number of BMs were identified as independent prognostic factors for survival. Conclusion Brain radiotherapy shows superior survival benefits for lung cancer patients with solid BMs compared to those with cystic BMs, particularly in EGFR-mutant lung cancer. In particular, patients receiving BED ≥60 Gy have a more favorable prognosis than those receiving BED <60 Gy, regardless of the type of BM (solid or cystic) in lung cancer.

show abstract

Case Report: Clinical and Procedural Implications of Ommaya Reservoir Implantation in Cystic Brain Metastases Followed by Radiosurgery Treatment

Cited by 2 publications

References 21 publications

Evaluation of radiotherapy efficacy and prognostic analysis for solid and cystic brain metastases

Evaluation of radiotherapy efficacy and prognostic analysis for solid and cystic brain metastases

Evaluation of Radiotherapy Efficacy and Prognostic Analysis for Solid and Cystic Brain Metastases

Contact Info

Product

Resources

About